Cytotoxicity, dose-enhancement and radiosensitization of glioblastoma cells with rare earth nanoparticles. Issue 1 (4th December 2019)

• Record Type: Journal Article
• Authors: Lu, Victor M.; Crawshay-Williams, Felicity; White, Benjamin; Elliot, Amy; Hill, Mark A.; Townley, Helen E.
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 47:Issue 1(2019)
• Page Start: 132
• Page End: 143
• Publication Date: 2019-12-04
• Subjects: Glioblastoma -- nanoparticle -- rare earth -- oncology -- radiotherapy; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2018.1544564
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Glioblastoma is a heterogeneous disease with multiple genotypic origins. Despite treatment protocols such as surgery, radiotherapy and chemotherapy, the prognosis for patients remains poor. This study investigates the cytotoxic and radiation dose-enhancing and radiosensitizing ability of five rare earth oxide nanoparticles, in two different immortalized mammalian cell lines; U-87 MG and Mo59K. Significant cytotoxicity was observed in U-87 MG cells when exposed to Nd2 O3 and La2 O3. Autophagy was also detected in cells after incubation with Nd2 O3. Radiosensitization was observed in U-87 MG when incubated with Gd2 O3, CeO2 -Gd and Nd2 O3 :Si. Importantly, these elements did not cause any intrinsic toxicity in the absence of irradiation and so could be considered biocompatible. The Gd2 O3 and CeO2 -Gd nanoparticles were also seen to generate ROS in U-87 MG cells after irradiation. Furthermore, the Mo59K and U-87 MG cells responded very differently to exposure to the rare earth nanoparticles. This may indicate the importance of the genotype of cells in the successful use of rare earth oxides for treatment.